DUBLIN, Feb. 8, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5tjz6p/global_gene) has announced the addition of the "Global Gene Therapy Partnering Terms and Agreements 2010 to 2016" company profile to their offering.

The Global Gene Therapy Partnering Terms and Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 250 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Global Gene Therapy Partnering Terms and Agreements includes:

• Trends in gene therapy dealmaking in the biopharma industry since 2010
• Analysis of gene therapy deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life gene therapy deals
• Access to over 250 gene therapy deals
• The leading antibody deals by value since 2010
• Most active gene therapy dealmakers since 2010
• The leading gene therapy partnering resources

In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy and technology target

For more information visit http://www.researchandmarkets.com/research/5tjz6p/global_gene

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets